The purpose of this study is to evaluate how well the vaccine continues to protect women over a long period of time by tracking whether they develop abnormal cervical cell changes or cervical cancer caused by the specific HPV types the vaccine targets. The study also aims to examine the body’s immune response to the vaccine over time and to monitor its safety. Additionally, researchers will look at whether the vaccine helps prevent abnormal cell changes and cancers caused by other HPV types not included in the vaccine, as well as cancers of the vulva and vagina.

Women who participated in an earlier study called V503-001 in Denmark, Norway, or Sweden and received either Gardasil 9 or an earlier version of the HPV vaccine will be followed through national health registries in these countries. This means their health information will be collected from official health records over many years without requiring regular study visits. Some participants may be contacted to provide blood samples so researchers can measure the levels of protective substances in their blood against the different HPV types. Tissue samples from any biopsies (small tissue samples taken during medical procedures) will also be analyzed to see if HPV is present and which type it is.

The purpose of the study is to evaluate the safety and immune response of different dosing schedules of the Gardasil 9 vaccine. The study compares a 2-dose regimen given to boys and girls aged 9 to 14 years with a standard 3-dose regimen given to young women aged 16 to 26 years. The study also looks at the immune response in boys and girls aged 10 to 15 years who have already received one dose of the vaccine at least a year before joining the study. Participants will receive the vaccine at different intervals, and their immune response will be measured to see how well the vaccine works over time.

Throughout the study, participants will be monitored for any side effects or adverse reactions to the vaccine. The study aims to ensure that the vaccine is safe and effective in preventing HPV-related diseases. Participants will receive the vaccine through an intramuscular injection, which means the shot is given directly into a muscle. The study will help determine the best dosing schedule for the Gardasil 9 vaccine to provide optimal protection against HPV.

The purpose of the study is to evaluate how well the 9-valent HPV vaccine works in these immunocompromised individuals. Participants will receive three doses of the vaccine over a period of several months. The study will monitor the participants’ immune response to the vaccine, specifically looking at how their bodies produce antibodies against the virus. This will be compared to the immune response of healthy individuals who also receive the vaccine.

Throughout the study, participants will have their blood tested at different times to measure the levels of antibodies and other immune markers. The study aims to provide valuable information on the effectiveness of the 9-valent HPV vaccine in protecting immunocompromised children and adolescents from HPV-related diseases. This research could help improve vaccination strategies for those with weakened immune systems, ensuring they receive the best possible protection against HPV.

Participants in the study will receive the Gardasil 9 vaccine, which is designed to protect against nine types of the Human Papillomavirus (HPV). The vaccine will be compared to a placebo to determine its effectiveness. The study will involve a series of injections over a period of several months, with the goal of observing the complete remission of warts one month after the third injection. The study will also monitor the quality of life, pain levels, and any changes in the number of warts over time.

The trial is intended for individuals who have had palmar or plantar warts for more than a year and have tried at least two other treatments without success. The study will last for several months, and participants will be regularly assessed to track the progress of their warts and any improvements in their condition. The ultimate goal is to determine if the nonavalent HPV vaccine can be an effective treatment option for these persistent warts.

The purpose of the study is to see if the HPV vaccine can help prevent the recurrence of vHSIL after women have been treated for it. Participants in the study will receive either the Gardasil 9 vaccine or a placebo, which is a substance with no active ingredients. The study will follow participants for up to 24 months to monitor for any recurrence of the condition. The vaccine is given as an injection into the muscle, and the study will involve several visits over the course of the trial period.

Throughout the study, researchers will compare the number of women who experience a return of vHSIL between those who receive the HPV vaccine and those who receive the placebo. They will also look at how the vaccine affects different types of HPV and whether it impacts the quality of life, sexual health, and productivity of the participants. The study aims to provide valuable information on the effectiveness of the HPV vaccine in preventing the recurrence of this condition and potentially improving the overall health outcomes for women affected by vHSIL.